Day Two - Wednesday 4th December, 2024 - GMT (Greenwich Mean Time, GMTZ)
Day Two - Wednesday 4th December, 2024 - GMT (Greenwich Mean Time, GMTZ)
Analyse CDMO partnership success factors. Evaluate outsourcing benefits versus in-house capabilities. Ensure scalability, consistency, and data security in CDMO collaborations. Provide access to GMP facilities for smaller companies.
Jazz Pharmaceuticals employ a risk based approach to new vendor onboarding – a technical deep dive to evaluate capabilities, identify risks and opportunities and establish mitigation / improvement plans, with a cross functional team across MS&T, QC / Analytical, Facilities and Utilities Eng and Process development.
- Derek Lonergan - Director, New Product Integration MS&T, Jazz Pharmaceuticals, Ireland
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact us today to learn more: Partners@informaconnectls.com
Explore cloud MES benefits and challenges. Evaluate vendor offerings. Consider MES-specific cloud requirements. Anticipate future trends.
- Brian Reynolds - Digital Manufacturing Lead, Johnson & Johnson, Ireland
Reduce commercial product shipping costs through strategic optimization. Implement sustainability initiatives. Validate and test supply chain reliability.
- Tatiana Maeda - Executive Director, Global Supply Chain, Process & Digital Excellence, Bristol-Myers Squibb, USA
Enhance Ireland's CGT profile through effective marketing. Leverage Irish location for CGT advantages.
- Frank Barry - Professor of Cellular Therapy, National University of Ireland Galway and Principle Investigator, Regenerative Medicine Institute (REMEDI), Ireland
Developing a skilled workforce, expanding talent pools, and leveraging government support for education are crucial to meet biomanufacturing demands.
- Shada Warreth - Global Partnerships Implementation Senior Manager, TU Dublin, NIBRT, Ireland
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact us today to learn more: Partners@informaconnectls.com
- How does this compare to EU funding i.e. EU seal of excellence / disruptive technologies investment?
- How are biotech companies securing funding in Ireland to promote innovation?
- Lifecycle management
- Reimbursement & Market access considerations
- How can we create links between academia, SMEs and pharma?
- Current funding landscape: VC, Angel, Grants, etc.
- Innovative funding mechanisms to balance risk and reward for investors and developers.
- Recovering from the Covid Bubble bursting
- Ensuring equitable access to advanced therapies across different economic landscapes
- The role of patient advocacy in shaping funding priorities and influencing investment decisions
- How can angel investors with smaller individual investments can work with larger VCs ticket size? Can these individual investors bring an insight that VCs don’t/can’t have?
- Eimear O'Leary - Director of Communications and Advocacy, Irish Pharmaceutical Healthcare Association, Ireland
- Sven Kili, MD - Partner, Saisei Ventures
- Eric Halioua - President & Chief Executive Officer, PDC*line Pharma
- Dr Hiro Usuda - Scouting & Transaction Lead, Business Development, Astellas Innovation Management LLC